comparison between 3 steroid injections for treating heel pain

Phase 4

Recruiting

Brief Summary: A prospective, randomized, three armed, comparative and open label study will be conducted. Study will be conducted as per ICH-GCP guidelines. Patients presenting with heel pain will be screened and clinical examination will be performed by the orthopaedic surgeons in the orthopaedic OPD. Clinically diagnosed cases of plantar fasciitis would then be subjected to investigations like X-ray, ultrasonography of heel, complete blood count, fasting and post meal sugar and serum uric acid levels for confirming the diagnosis and for finding the pathology. Patients fulfilling the inclusion criteria would be enrolled in the study. Written informed consent in patients own language will be obtained. Three groups of 20 patients each will be made. Randomization will be done using chit method. Group A patients would be given injection Methyl prednisolone 40 mg stat in heel, Group B patients would be given injection Triamcinolone 40 mg stat in heel and Group C patients would be given injection Dexamethasone 4 mg stat in heel. All injections will be given by orthopaedic surgeons in procedure room under all aseptic precautions.

Pain intensity will be assessed at start, at 2 weeks and at 4 weeks of starting the treatment using:

Â· Visual analogue scale (VAS)

Recruitment & Eligibility

Inclusion Criteria

1.Patient willing to participate in the study and give consent.
2.Age group of 18-65 years of either sex.
3.Diagnosed cases of plantar fasciitis having symptoms for > 6 weeks.
4.Patients who had a fair trial of other conservative treatment but got no relief.

Exclusion Criteria

1.Pregnant and lactating women.
2.Patients who are immunocompromised.
3.Patients with history of diabetes, hypertension and tuberculosis.
4.Patient having history of infection in last 3 months 5.Patients with history of psychiatric disorders.
6.Patient with history of peptic ulcer 7.Patients with history of osteoporosis.
8.Patients with history of trauma to heel.

Primary Outcome Measures

Name	Time	Method
reduction in pain	At the end of 2 and 4 weeks

Secondary Outcome Measures

Name	Time	Method
reduction in discomfort	At the end of 2 and 4 weeks

Locations (2): Department of orthopaedics
🇮🇳
Aurangabad, MAHARASHTRA, India
Department of Pharmacology
🇮🇳
Aurangabad, MAHARASHTRA, India
Department of orthopaedics
🇮🇳Aurangabad, MAHARASHTRA, India
Dr Deepak bhosle
Principal investigator
9049484204
drdeepakbhosle@gmail.com